{"product_id":"tarceva","title":"Tarceva","description":"\u003ch3 data-start=\"276\" data-end=\"300\"\u003eWhat is Erlotinib?\u003c\/h3\u003e\r\n\u003cp data-start=\"301\" data-end=\"624\"\u003e\u003cstrong data-start=\"301\" data-end=\"314\"\u003eErlotinib\u003c\/strong\u003e is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) used primarily in the treatment of non‑small cell lung cancer (NSCLC) and pancreatic cancer. By inhibiting EGFR signaling, erlotinib slows tumor growth and helps improve patient outcomes in cancers that express EGFR mutations.\u003c\/p\u003e\r\n\u003cp data-start=\"626\" data-end=\"719\"\u003e\u003cem data-start=\"626\" data-end=\"719\"\u003eReference: U.S. FDA Tarceva Prescribing Information; ClinicalTrials.gov (e.g., NCT00322452)\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"721\" data-end=\"724\"\u003e\r\n\u003ch3 data-start=\"726\" data-end=\"779\"\u003eWhat are the other popular names for Erlotinib?\u003c\/h3\u003e\r\n\u003cp data-start=\"780\" data-end=\"927\"\u003eErlotinib is most widely marketed under the brand name \u003cstrong data-start=\"835\" data-end=\"847\"\u003eTarceva®\u003c\/strong\u003e. In clinical literature, it is also referred to by its generic name, erlotinib.\u003c\/p\u003e\r\n\u003cp data-start=\"929\" data-end=\"963\"\u003e\u003cem data-start=\"929\" data-end=\"963\"\u003eReference: MedlinePlus; U.S. FDA\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"965\" data-end=\"968\"\u003e\r\n\u003ch3 data-start=\"970\" data-end=\"1021\"\u003eWhat is the drug classification of Erlotinib?\u003c\/h3\u003e\r\n\u003cp data-start=\"1022\" data-end=\"1217\"\u003eErlotinib is classified as an \u003cstrong data-start=\"1052\" data-end=\"1092\"\u003eEGFR tyrosine kinase inhibitor (TKI)\u003c\/strong\u003e. It belongs to the class of targeted anticancer agents used primarily in oncology for the treatment of EGFR‑mutated cancers.\u003c\/p\u003e\r\n\u003cp data-start=\"1219\" data-end=\"1293\"\u003e\u003cem data-start=\"1219\" data-end=\"1293\"\u003eReference: World Health Organization (WHO) Oncology Guidelines; U.S. FDA\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"1295\" data-end=\"1298\"\u003e\r\n\u003ch3 data-start=\"1300\" data-end=\"1346\"\u003eWhat is the mode of action of Erlotinib?\u003c\/h3\u003e\r\n\u003cp data-start=\"1347\" data-end=\"1752\"\u003eErlotinib functions by competitively binding to the ATP-binding site of the intracellular domain of the EGFR. This binding inhibits receptor autophosphorylation and downstream signaling pathways (such as the MAPK and PI3K\/AKT pathways), which are critical for tumor cell proliferation, survival, and metastasis. This inhibition leads to reduced tumor growth and increased apoptosis in EGFR‑driven cancers.\u003c\/p\u003e\r\n\u003cp data-start=\"1754\" data-end=\"1818\"\u003e\u003cem data-start=\"1754\" data-end=\"1818\"\u003eReference: PubMed (Lynch et al., 2004, N Engl J Med); U.S. FDA\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"1820\" data-end=\"1823\"\u003e\r\n\u003ch3 data-start=\"1825\" data-end=\"1870\"\u003eWhat are the primary uses of Erlotinib?\u003c\/h3\u003e\r\n\u003cp data-start=\"1871\" data-end=\"1910\"\u003eErlotinib is primarily indicated for:\u003c\/p\u003e\r\n\u003cul data-start=\"1911\" data-end=\"2177\"\u003e\r\n\u003cli data-start=\"1911\" data-end=\"2051\"\u003e\n\u003cstrong data-start=\"1913\" data-end=\"1952\"\u003eNon‑Small Cell Lung Cancer (NSCLC):\u003c\/strong\u003e Particularly in patients with advanced or metastatic NSCLC harboring EGFR-sensitizing mutations.\u003c\/li\u003e\r\n\u003cli data-start=\"2052\" data-end=\"2177\"\u003e\n\u003cstrong data-start=\"2054\" data-end=\"2076\"\u003ePancreatic Cancer:\u003c\/strong\u003e In combination with gemcitabine for locally advanced, unresectable, or metastatic pancreatic cancer.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"2179\" data-end=\"2252\"\u003e\u003cem data-start=\"2179\" data-end=\"2252\"\u003eReference: U.S. FDA Tarceva Prescribing Information; ClinicalTrials.gov\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"2254\" data-end=\"2257\"\u003e\r\n\u003ch3 data-start=\"2259\" data-end=\"2329\"\u003eWhat is the recommended dosage and administration for Erlotinib?\u003c\/h3\u003e\r\n\u003cul data-start=\"2330\" data-end=\"2728\"\u003e\r\n\u003cli data-start=\"2330\" data-end=\"2406\"\u003e\n\u003cstrong data-start=\"2332\" data-end=\"2353\"\u003eDosage for NSCLC:\u003c\/strong\u003e The standard oral dosage is \u003cstrong data-start=\"2382\" data-end=\"2403\"\u003e150 mg once daily\u003c\/strong\u003e.\u003c\/li\u003e\r\n\u003cli data-start=\"2407\" data-end=\"2527\"\u003e\n\u003cstrong data-start=\"2409\" data-end=\"2442\"\u003eDosage for Pancreatic Cancer:\u003c\/strong\u003e Often used at the same dosage (150 mg once daily) in combination with gemcitabine.\u003c\/li\u003e\r\n\u003cli data-start=\"2528\" data-end=\"2728\"\u003e\n\u003cstrong data-start=\"2530\" data-end=\"2549\"\u003eAdministration:\u003c\/strong\u003e\r\n\u003cul data-start=\"2554\" data-end=\"2728\"\u003e\r\n\u003cli data-start=\"2554\" data-end=\"2667\"\u003eErlotinib should be taken on an empty stomach (1 hour before or 2 hours after a meal) to maximize absorption.\u003c\/li\u003e\r\n\u003cli data-start=\"2670\" data-end=\"2728\"\u003eConsistent daily dosing at the same time is recommended.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"2730\" data-end=\"2823\"\u003e\u003cem data-start=\"2730\" data-end=\"2823\"\u003eReference: U.S. FDA Tarceva Prescribing Information; ClinicalTrials.gov (e.g., NCT00322452)\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"2825\" data-end=\"2828\"\u003e\r\n\u003ch3 data-start=\"2830\" data-end=\"2892\"\u003eWhat prescribing information is important for Erlotinib?\u003c\/h3\u003e\r\n\u003cul data-start=\"2893\" data-end=\"3509\"\u003e\r\n\u003cli data-start=\"2893\" data-end=\"3033\"\u003e\n\u003cstrong data-start=\"2895\" data-end=\"2911\"\u003eIndications:\u003c\/strong\u003e\r\n\u003cul data-start=\"2916\" data-end=\"3033\"\u003e\r\n\u003cli data-start=\"2916\" data-end=\"3033\"\u003eApproved for advanced NSCLC with EGFR mutations and for use in combination with gemcitabine in pancreatic cancer.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"3034\" data-end=\"3163\"\u003e\n\u003cstrong data-start=\"3036\" data-end=\"3058\"\u003eContraindications:\u003c\/strong\u003e\r\n\u003cul data-start=\"3063\" data-end=\"3163\"\u003e\r\n\u003cli data-start=\"3063\" data-end=\"3163\"\u003eContraindicated in patients with a known hypersensitivity to erlotinib or any of its components.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"3164\" data-end=\"3294\"\u003e\n\u003cstrong data-start=\"3166\" data-end=\"3181\"\u003eMonitoring:\u003c\/strong\u003e\r\n\u003cul data-start=\"3186\" data-end=\"3294\"\u003e\r\n\u003cli data-start=\"3186\" data-end=\"3294\"\u003eRegular monitoring of liver function, complete blood counts, and dermatologic assessments are necessary.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"3295\" data-end=\"3509\"\u003e\n\u003cstrong data-start=\"3297\" data-end=\"3324\"\u003eSpecial Considerations:\u003c\/strong\u003e\r\n\u003cul data-start=\"3329\" data-end=\"3509\"\u003e\r\n\u003cli data-start=\"3329\" data-end=\"3435\"\u003eEGFR mutation testing is recommended prior to treatment in NSCLC to identify patients likely to benefit.\u003c\/li\u003e\r\n\u003cli data-start=\"3438\" data-end=\"3509\"\u003eDose adjustments may be required in patients with hepatic impairment.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"3511\" data-end=\"3581\"\u003e\u003cem data-start=\"3511\" data-end=\"3581\"\u003eReference: U.S. FDA Tarceva Prescribing Information; NCCN Guidelines\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"3583\" data-end=\"3586\"\u003e\r\n\u003ch3 data-start=\"3588\" data-end=\"3686\"\u003eWhat safety information, side effects, warnings, and cautions are associated with Erlotinib?\u003c\/h3\u003e\r\n\u003cul data-start=\"3687\" data-end=\"4756\"\u003e\r\n\u003cli data-start=\"3687\" data-end=\"3809\"\u003e\n\u003cstrong data-start=\"3689\" data-end=\"3713\"\u003eCommon Side Effects:\u003c\/strong\u003e\r\n\u003cul data-start=\"3718\" data-end=\"3809\"\u003e\r\n\u003cli data-start=\"3718\" data-end=\"3809\"\u003eSkin rash (often acneiform), diarrhea, nausea, vomiting, loss of appetite, and fatigue.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"3810\" data-end=\"3996\"\u003e\n\u003cstrong data-start=\"3812\" data-end=\"3837\"\u003eSerious Side Effects:\u003c\/strong\u003e\r\n\u003cul data-start=\"3842\" data-end=\"3996\"\u003e\r\n\u003cli data-start=\"3842\" data-end=\"3996\"\u003eInterstitial lung disease (ILD)\/pneumonitis, which can be life‑threatening; severe skin reactions (e.g., Stevens-Johnson syndrome) and liver toxicity.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"3997\" data-end=\"4587\"\u003e\n\u003cstrong data-start=\"3999\" data-end=\"4023\"\u003eWarnings \u0026amp; Cautions:\u003c\/strong\u003e\r\n\u003cul data-start=\"4028\" data-end=\"4587\"\u003e\r\n\u003cli data-start=\"4028\" data-end=\"4147\"\u003e\n\u003cstrong data-start=\"4030\" data-end=\"4053\"\u003ePulmonary Toxicity:\u003c\/strong\u003e Monitor for new or worsening respiratory symptoms; discontinue therapy if ILD is suspected.\u003c\/li\u003e\r\n\u003cli data-start=\"4150\" data-end=\"4245\"\u003e\n\u003cstrong data-start=\"4152\" data-end=\"4179\"\u003eDermatologic Reactions:\u003c\/strong\u003e Severe skin rash may require dose reduction or discontinuation.\u003c\/li\u003e\r\n\u003cli data-start=\"4248\" data-end=\"4363\"\u003e\n\u003cstrong data-start=\"4250\" data-end=\"4269\"\u003eHepatotoxicity:\u003c\/strong\u003e Regular liver function tests are essential; significant abnormalities warrant intervention.\u003c\/li\u003e\r\n\u003cli data-start=\"4366\" data-end=\"4481\"\u003e\n\u003cstrong data-start=\"4368\" data-end=\"4381\"\u003eDiarrhea:\u003c\/strong\u003e Can lead to dehydration; advise patients to maintain hydration and seek medical advice if severe.\u003c\/li\u003e\r\n\u003cli data-start=\"4484\" data-end=\"4587\"\u003e\n\u003cstrong data-start=\"4486\" data-end=\"4508\"\u003eDrug Interactions:\u003c\/strong\u003e Concomitant use with CYP3A4 inhibitors or inducers may alter erlotinib levels.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"4588\" data-end=\"4756\"\u003e\n\u003cstrong data-start=\"4590\" data-end=\"4604\"\u003ePregnancy:\u003c\/strong\u003e\r\n\u003cul data-start=\"4609\" data-end=\"4756\"\u003e\r\n\u003cli data-start=\"4609\" data-end=\"4756\"\u003eErlotinib is contraindicated in pregnancy due to potential teratogenic effects; women of childbearing potential must use effective contraception.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"4758\" data-end=\"4825\"\u003e\u003cem data-start=\"4758\" data-end=\"4825\"\u003eReference: U.S. FDA Tarceva Prescribing Information; NEJM; PubMed\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"4827\" data-end=\"4830\"\u003e\r\n\u003ch3 data-start=\"4832\" data-end=\"4897\"\u003eWhat drug interactions should be considered with Erlotinib?\u003c\/h3\u003e\r\n\u003cul data-start=\"4898\" data-end=\"5291\"\u003e\r\n\u003cli data-start=\"4898\" data-end=\"5055\"\u003e\n\u003cstrong data-start=\"4900\" data-end=\"4922\"\u003eCYP3A4 Inhibitors:\u003c\/strong\u003e\r\n\u003cul data-start=\"4927\" data-end=\"5055\"\u003e\r\n\u003cli data-start=\"4927\" data-end=\"5055\"\u003eStrong inhibitors (e.g., ketoconazole, clarithromycin) can increase erlotinib plasma levels, enhancing the risk of toxicity.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"5056\" data-end=\"5178\"\u003e\n\u003cstrong data-start=\"5058\" data-end=\"5078\"\u003eCYP3A4 Inducers:\u003c\/strong\u003e\r\n\u003cul data-start=\"5083\" data-end=\"5178\"\u003e\r\n\u003cli data-start=\"5083\" data-end=\"5178\"\u003eInducers (e.g., rifampin, carbamazepine) may lower erlotinib levels, reducing its efficacy.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"5179\" data-end=\"5291\"\u003e\n\u003cstrong data-start=\"5181\" data-end=\"5203\"\u003eOther Medications:\u003c\/strong\u003e\r\n\u003cul data-start=\"5208\" data-end=\"5291\"\u003e\r\n\u003cli data-start=\"5208\" data-end=\"5291\"\u003eCaution with drugs that may compound gastrointestinal toxicity or hepatotoxicity.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"5293\" data-end=\"5355\"\u003e\u003cem data-start=\"5293\" data-end=\"5355\"\u003eReference: U.S. FDA; Clinical Pharmacology Reviews on PubMed\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"5357\" data-end=\"5360\"\u003e\r\n\u003ch3 data-start=\"5362\" data-end=\"5399\"\u003eFrequently Asked Questions (FAQs)\u003c\/h3\u003e\r\n\u003cp data-start=\"5401\" data-end=\"5602\"\u003e\u003cstrong data-start=\"5401\" data-end=\"5451\"\u003eQ: How soon will I see results with Erlotinib?\u003c\/strong\u003e\u003cbr data-start=\"5451\" data-end=\"5454\"\u003eA: Improvement in symptoms may occur within a few weeks, though maximum benefit in tumor response might take several months of continuous treatment.\u003c\/p\u003e\r\n\u003cp data-start=\"5604\" data-end=\"5781\"\u003e\u003cstrong data-start=\"5604\" data-end=\"5644\"\u003eQ: Can Erlotinib be taken with food?\u003c\/strong\u003e\u003cbr data-start=\"5644\" data-end=\"5647\"\u003eA: For optimal absorption, it is recommended that erlotinib be taken on an empty stomach—either 1 hour before or 2 hours after a meal.\u003c\/p\u003e\r\n\u003cp data-start=\"5783\" data-end=\"6003\"\u003e\u003cstrong data-start=\"5783\" data-end=\"5839\"\u003eQ: What should I do if I develop a severe skin rash?\u003c\/strong\u003e\u003cbr data-start=\"5839\" data-end=\"5842\"\u003eA: Contact your healthcare provider immediately. Severe rash may indicate a need for dose adjustment or discontinuation due to risk of serious adverse reactions.\u003c\/p\u003e\r\n\u003cp data-start=\"6005\" data-end=\"6190\"\u003e\u003cstrong data-start=\"6005\" data-end=\"6073\"\u003eQ: Is EGFR mutation testing necessary before starting Erlotinib?\u003c\/strong\u003e\u003cbr data-start=\"6073\" data-end=\"6076\"\u003eA: Yes, EGFR mutation testing is essential to ensure that the patient is likely to benefit from erlotinib therapy.\u003c\/p\u003e\r\n\u003cp data-start=\"6192\" data-end=\"6399\"\u003e\u003cstrong data-start=\"6192\" data-end=\"6272\"\u003eQ: What precautions should I take regarding liver health while on Erlotinib?\u003c\/strong\u003e\u003cbr data-start=\"6272\" data-end=\"6275\"\u003eA: Regular liver function tests are important; report any symptoms such as jaundice, severe fatigue, or dark urine promptly.\u003c\/p\u003e\r\n\u003cp data-start=\"6401\" data-end=\"6595\"\u003e\u003cstrong data-start=\"6401\" data-end=\"6443\"\u003eQ: How should missed doses be managed?\u003c\/strong\u003e\u003cbr data-start=\"6443\" data-end=\"6446\"\u003eA: If you miss a dose, take it as soon as you remember, unless it is nearly time for your next dose. Do not double doses to make up for a missed one.\u003c\/p\u003e\r\n\u003cp data-start=\"6597\" data-end=\"6643\"\u003e\u003cem data-start=\"6597\" data-end=\"6643\"\u003eReference: U.S. FDA; NCCN Guidelines; PubMed\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"6645\" data-end=\"6648\"\u003e\r\n\u003ch3 data-start=\"6650\" data-end=\"6743\"\u003eWhere can I find additional clinical evidence and detailed information about Erlotinib?\u003c\/h3\u003e\r\n\u003cp data-start=\"6744\" data-end=\"6845\"\u003eFor further details on clinical studies, dosing guidelines, and safety monitoring, please refer to:\u003c\/p\u003e\r\n\u003cul data-start=\"6846\" data-end=\"7231\"\u003e\r\n\u003cli data-start=\"6846\" data-end=\"6934\"\u003e\n\u003cstrong data-start=\"6848\" data-end=\"6900\"\u003eU.S. Food and Drug Administration (FDA) Website:\u003c\/strong\u003e \u003ca href=\"https:\/\/www.fda.gov\/\" target=\"_new\" rel=\"noopener\" data-start=\"6901\" data-end=\"6932\"\u003eFDA.gov\u003c\/a\u003e\n\u003c\/li\u003e\r\n\u003cli data-start=\"6935\" data-end=\"6995\"\u003e\n\u003cstrong data-start=\"6937\" data-end=\"6960\"\u003eClinicalTrials.gov:\u003c\/strong\u003e (e.g., NCT00322452, NCT00121090)\u003c\/li\u003e\r\n\u003cli data-start=\"6996\" data-end=\"7060\"\u003e\n\u003cstrong data-start=\"6998\" data-end=\"7009\"\u003ePubMed:\u003c\/strong\u003e For peer‑reviewed research articles on erlotinib\u003c\/li\u003e\r\n\u003cli data-start=\"7061\" data-end=\"7138\"\u003e\n\u003cstrong data-start=\"7063\" data-end=\"7099\"\u003eWorld Health Organization (WHO):\u003c\/strong\u003e Guidelines on lung cancer management\u003c\/li\u003e\r\n\u003cli data-start=\"7139\" data-end=\"7231\"\u003e\n\u003cstrong data-start=\"7141\" data-end=\"7201\"\u003eNational Comprehensive Cancer Network (NCCN) Guidelines:\u003c\/strong\u003e For NSCLC treatment protocols\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"7233\" data-end=\"7299\"\u003e\u003cem data-start=\"7233\" data-end=\"7299\"\u003eReference: U.S. FDA; ClinicalTrials.gov; NEJM; PubMed; NCCN; WHO\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"7301\" data-end=\"7304\"\u003e\r\n\u003ch3 data-start=\"7306\" data-end=\"7326\"\u003eFinal Thoughts\u003c\/h3\u003e\r\n\u003cp data-start=\"7327\" data-end=\"7992\"\u003e\u003cstrong data-start=\"7327\" data-end=\"7340\"\u003eGefitinib\u003c\/strong\u003e is not to be confused with erlotinib; however, \u003cstrong data-start=\"7388\" data-end=\"7411\"\u003eErlotinib (Tarceva®)\u003c\/strong\u003e remains a cornerstone in targeted therapy for non‑small cell lung cancer with EGFR mutations. Its mechanism of action—blocking EGFR tyrosine kinase activity—leads to inhibition of tumor growth and enhanced apoptosis in cancer cells. With careful patient selection, regular monitoring for adverse effects (particularly interstitial lung disease and hepatotoxicity), and appropriate management of drug interactions, erlotinib can significantly improve clinical outcomes. Always consult your healthcare provider to ensure that erlotinib is the appropriate therapy for your condition.\u003c\/p\u003e\r\n\u003cp data-start=\"7994\" data-end=\"8207\"\u003e\u003cem data-start=\"7994\" data-end=\"8207\"\u003eDisclaimer: This guide is intended for educational purposes only and should not replace professional medical advice. Always consult your healthcare provider before initiating or modifying any medication regimen.\u003c\/em\u003e\u003c\/p\u003e","brand":"EZ Chemist","offers":[{"title":"150MG","offer_id":51735711645979,"sku":"TARCEVA150mg-1","price":3300.0,"currency_code":"USD","in_stock":true},{"title":"100mg","offer_id":51735711678747,"sku":"config-tarceva-brand-100mg","price":2850.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0992\/3303\/8619\/files\/untitled_design_81__1.png?v=1770407545","url":"https:\/\/ezchemist.com\/products\/tarceva","provider":"EZ Chemist","version":"1.0","type":"link"}